U.S. market Closed. Opens in 21 hours 12 minutes

REGN | Regeneron Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 631.43 - 642.63
52 Week Range 629.02 - 1,211.20
Beta 0.32
Implied Volatility 36.77%
IV Rank 65.75%
Day's Volume 535,903
Average Volume 932,888
Shares Outstanding 107,508,000
Market Cap 68,521,298,880
Sector Healthcare
Industry Biotechnology
IPO Date 1991-04-02
Valuation
Profitability
Growth
Health
P/E Ratio 16.61
Forward P/E Ratio 23.44
EPS 38.37
1YR Price Target 808.50
Dividend Yield 0.55%
Dividend Per Share 3.53
Dividend ExDate N/A
Dividend PayDate N/A
Employees 14,165
Country USA
Website REGN
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
*Chart delayed
Analyzing fundamentals for REGN we got that it has strong fundamentals where Valuation is considered to be undervalued, Profitability is very wealthy, Growth is exceptionally good and Health is very strong. For more detailed analysis please see REGN Fundamentals page.

Watching at REGN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on REGN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙